期刊文献+

枸橼酸西地那非及关键中间体合成工艺的改进 被引量:3

The improvement of synthesis process for sildenafil citrate and its key intermediate
下载PDF
导出
摘要 目的对枸橼酸西地那非及关键中间体西地那非合成工艺进行优化改进。方法以邻乙氧基苯甲酰氯与4-氨基-1-甲基-3-正丙基-1H-吡唑-5-甲酰胺为起始物料,经缩合、环合、氯磺化、磺酰胺化、成盐等一系列反应,制备枸橼酸西地那非。结果关键中间体西地那非纯度在99.5%以上,杂质D(《欧洲药典》)控制在0.3%以下,其他单杂控制在0.15%以下。结论用精制后西地那非制备出枸橼酸西地那非,纯度在99.8%以上,总收率在45%以上。此工艺成本低,容易操作,且适合工业化生产。 Objective To optimize and improve the synthesis process for sildenafil citrate and its key intermediate sildenafil.Methods The sildenafil citrate was prepared from the raw materials of 2-ethoxybenzoyl chloride and 4-amino-1- methyl-3-n-propyl-5-pyrazolecarboxamide by the reactions of condensation, cyclization,chlorosulfonation, sulfonamide and salt.Results The purity of the key intermediate sildenafil was higher than 99.5%, impurity D(EP) was lower than 0.3% and the unspecified single impurity was lower than 0.15%.Conclusion The purity of the sildenafil citrate was above 99.8% and the total yield was 45%.The process was low cost,easy operate and suitable for industrialized production.
作者 徐莉莉 汪海洋 孔意 姚庆强 XU Lili WANG Haiyang KONG Yi YAO Qingqiang(School of Medicine and Life Sciences, Shandong Academy of Medical Sciences, University of Jinan, Jinan 250022, China Institute of Materia Medica , Shandong Academy of Medical Sciences, Jinan 250062, China Zhangqiu People's Hospital, Jinan 250200, China Jinan Mingxin Pharmaceutical Co., Ltd. , Jinan 250216, China)
出处 《药学研究》 CAS 2017年第10期618-620,共3页 Journal of Pharmaceutical Research
关键词 枸橼酸西地那非 关键中间体 杂质D 合成工艺 改进 Sildenafil citrate Key intermediate Impurity D Synthesis process Improvemen
  • 相关文献

参考文献7

二级参考文献56

  • 1杨秀春,崔炜.西地那非在肺动脉高压中的应用[J].心血管病学进展,2005,26(4):357-359. 被引量:5
  • 2孙曰圣,陈心勇,肖鉴谋,许金发,吕德新,周公贤.1-甲基-3-正丙基吡唑-5-甲酸的合成[J].化学世界,2005,46(10):611-613. 被引量:3
  • 3曾嵘,庄建,岑坚正,陈欣欣,熊卫萍,朱卫中.枸橼酸西地那非治疗心脏手术后肺动脉高压的临床研究[J].中华心血管病杂志,2005,33(10):916-919. 被引量:28
  • 4蒋雷服,殷凯生.西地那非治疗肺动脉高压的研究进展[J].国际内科学杂志,2007,34(4):220-223. 被引量:11
  • 5[1]Robert B, Moreland I, Abdulmaged T. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells [J]. Life Science, 1988,62(60):PL309-318.
  • 6[2]Bell AS, Brown D, Terrett N K. Pyrazolopyrimidinones antianginal agents [P]. EP: 463756, 1991-06-07.
  • 7[3]Bell AS, Terrett N K. Pyrazolopyrimidinones antianginal agents[P]. EP:526004,1992-07-02.
  • 8[4]Kunio S, Junichi I, Minoru F. Studies on hypolidemic agents.Ⅱ. Synthesis and pharmacological properties of alkyl pyrazole derivatives [J]. Chem Pharma Bull, 1984,32(4):1568-1577.
  • 9[5]Harriet WH, Daniel FO, Donald FW. Synthesis and structure-activity relationships of pyrazolo[4,3-d]pyrimidine-7-ones as adenosine recepter antagonists [J]. J Med Chem, 1987,30:91-96.
  • 10Terrett NK,Bell AS,Brown D,et al.Sildenafil(VIAGRATM),a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction[J].Bioorg Med Chem Lett,1996,6(15):1819-1824.

共引文献32

同被引文献37

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部